GlassScriptPhysician profile
Carol Foster
NPI 1407838790
$4,479.08
in general payments reported to CMS, 2019-2025
27 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $762 · 2021: $1,635 · 2022: $359 · 2023: $617 · 2024: $500 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,723.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,260.68 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $606.57 | 2020-2021 | |
| Allergan, INC. | $396.76 | 2020-2021 | |
| Lilly USA, LLC | $298.19 | 2020-2024 | Amyvid, Emgality, Reyvow |
| Amgen INC. | $281.84 | 2020-2021 | |
| Pfizer INC. | $266.81 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $206.91 | 2020-2021 | |
| Sk Life Science, INC. | $164.81 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $134.51 | 2023-2024 | Rexulti, Nuedexta |
| Genzyme Corporation | $115.80 | 2021-2022 | |
| Ucb, INC. | $86.42 | 2023-2024 | Nayzilam, Fintepla |
| Biohaven Pharmaceutical Holding Company LTD. | $83.53 | 2022 | |
| Supernus Pharmaceuticals, INC. | $82.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $79.56 | 2021 | |
| Currax Pharmaceuticals LLC | $75.05 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $47.06 | 2023 | Trudhesa |
| Avanir Pharmaceuticals, INC. | $44.03 | 2021 | |
| Assertio Therapeutics, INC. | $35.45 | 2020 | |
| Upsher-Smith Laboratories LLC | $30.84 | 2021 | |
| Averitas Pharma INC. | $29.87 | 2025 | Qutenza |
| Janssen Pharmaceuticals, INC | $25.36 | 2021 | |
| Biogen, INC. | $24.27 | 2021 | |
| Lundbeck LLC | $23.91 | 2024 | Vyepti |
| Scilex Pharmaceuticals INC. | $23.76 | 2021 | |
| Emd Serono, INC. | $21.01 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.93 | 2025 | Lokelma |
| Tonix Medicines, INC. | $16.52 | 2025 | Zembrace Symtouch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.